LGR4
Leucine-rich repeat-containing G protein-coupled receptor 4
As of the edition of 20 October 2026, LGR4 (leucine-rich repeat-containing G protein-coupled receptor 4, UniProt Q9BXB1) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9BXB1
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 23
- Disease areas
- Cancer; Digestive system
- Registered trials of its drugs
- 1
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rosmantuzumab | Went quiet | Phase 1 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |